241 related articles for article (PubMed ID: 36142442)
1. Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia.
Weeda V; Mestrum SGC; Leers MPG
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142442
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic features of leukemic stem cells and bulk of blasts in acute myeloid leukemia.
Ivanivska TS; Sklyarenko LM; Zavelevich MP; Philchenkov AA; Koval SV; Polishchuk AS; Gluzman DF
Exp Oncol; 2019 Sep; 41(3):207-209. PubMed ID: 31569935
[TBL] [Abstract][Full Text] [Related]
3. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia.
Hoffmann MH; Klausen TW; Boegsted M; Larsen SF; Schmitz A; Leinoe EB; Schmiegelow K; Hasle H; Bergmann OJ; Sorensen S; Nyegaard M; Dybkaer K; Johnsen HE
Cytometry B Clin Cytom; 2012 May; 82(3):123-31. PubMed ID: 22328535
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotyping by Multiparameter Flow Cytometry.
Chen W; Luu HS
Methods Mol Biol; 2017; 1633():51-73. PubMed ID: 28735480
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Terstappen LW; Safford M; Könemann S; Loken MR; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Leukemia; 1992 Jan; 6(1):70-80. PubMed ID: 1540262
[TBL] [Abstract][Full Text] [Related]
7. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
8. Characterization of aberrant phenotypes in acute myeloblastic leukemia.
Macedo A; Orfão A; Vidriales MB; López-Berges MC; Valverde B; González M; Caballero MD; Ramos F; Martínez M; Fernández-Calvo J
Ann Hematol; 1995 Apr; 70(4):189-94. PubMed ID: 7748963
[TBL] [Abstract][Full Text] [Related]
9. Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia.
Ouyang G; Xu Z; Jiang D; Zhu H; Wang Y; Wu W; Sun Y; Sheng L; Xu K; Lou Y; Mu Q; Zhang Y; Wu N; Cheng J; Duan S
J Int Med Res; 2019 Apr; 47(4):1483-1492. PubMed ID: 30614357
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte colony-stimulating factor receptors on human acute leukemia: biphenotypic leukemic cells possess granulocyte colony-stimulating factor receptors.
Shimoda K; Okamura S; Harada N; Ikematsu W; Kondo S; Kawasaki C; Tanaka T; Etou T; Akashi K; Okamura T
Cancer Res; 1992 Jun; 52(11):3052-5. PubMed ID: 1534271
[TBL] [Abstract][Full Text] [Related]
11. The value of dot plot patterns and leukemia-associated phenotypes in AML diagnosis by multiparameter flow cytometry.
Zelezníková T; Babusíková O
Neoplasma; 2005; 52(6):517-22. PubMed ID: 16284699
[TBL] [Abstract][Full Text] [Related]
12. Antigen expression on a putative leukemic stem cell population and AML blast.
Garg S; Ghosh K; Madkaikar M
Int J Hematol; 2016 May; 103(5):567-71. PubMed ID: 26910244
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
[TBL] [Abstract][Full Text] [Related]
14. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin.
Bühring HJ; Kuçi S; Conze T; Rathke G; Bartolović K; Grünebach F; Scherl-Mostageer M; Brümmendorf TH; Schweifer N; Lammers R
Stem Cells; 2004; 22(3):334-43. PubMed ID: 15153610
[TBL] [Abstract][Full Text] [Related]
15. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies.
Macedo A; Orfão A; Gonzalez M; Vidriales MB; López-Berges MC; Martínez A; San Miguel JF
Leukemia; 1995 Jun; 9(6):993-8. PubMed ID: 7596191
[TBL] [Abstract][Full Text] [Related]
16. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up.
Larsen HØ; Roug AS; Just T; Brown GD; Hokland P
Cytometry B Clin Cytom; 2012 Jan; 82(1):3-8. PubMed ID: 22173921
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
18. OMIP 072: A 15-color panel for immunophenotypic identification, quantification, and characterization of leukemic stem cells in children with acute myeloid leukemia.
Petersen MA; Bill M; Rosenberg CA
Cytometry A; 2021 Apr; 99(4):382-387. PubMed ID: 33369057
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts.
Fajtova M; Babusikova O
Neoplasma; 2010; 57(5):392-400. PubMed ID: 20568892
[TBL] [Abstract][Full Text] [Related]
20. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
Terwijn M; Zeijlemaker W; Kelder A; Rutten AP; Snel AN; Scholten WJ; Pabst T; Verhoef G; Löwenberg B; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
PLoS One; 2014; 9(9):e107587. PubMed ID: 25244440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
